A recent study using a combination of orally administered GABA with alum-formulated human recombinant GAD65 (GAD65 Alum) in newly diagnosed T1D pediatric patients (GABA: 41 patients, GABA+GAD65 Alum: 25 patients, placebo: 31 patients) showed a significant reduction in fasting and meal-stimulated glucagon levels compared with control (Martin et al, 2022). This evidence concerns the gene GCG and type 1 diabetes mellitus.